Please login to the form below

Not currently logged in


This page shows the latest Kesimpta news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

Kesimpta is the first subcutaneous B-cell therapy that can be self-administered at home for people with RRMS. ... The overall fatal outcome (0.8%) and hospitalisation rates (9.4%) due to COVID-19 in Kesimpta-treated patients were lower than the rates

Latest news

More from news
Approximately 4 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Reaching patients and HCPs during the pandemic Reaching patients and HCPs during the pandemic

    Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...